fludarabine has been researched along with alvocidib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Byrd, JC; Diehl, LF; Flinn, IW; Fuchs, EJ; Grever, MR; Lehman, TA; Nguyen, PL; Sausville, E; Shinn, C; Waselenko, JK | 1 |
| Bentley, P; Fegan, C; Hoy, T; Pepper, C; Thomas, A | 1 |
| Croce, C | 1 |
| Blum, KA; Brooker-McEldowney, M; Byrd, JC; Dalton, JT; Farley, KL; Fischer, B; Grever, MR; Heerema, NA; Hurh, E; Jarjoura, D; Johnson, AJ; Lin, TS; Mitchell, SM; Moran, ME; Phelps, MA; Rozewski, DM; Schaaf, LJ; Wu, D | 1 |
| Baiocchi, RA; Blum, KA; Byrd, JC; Fischer, DB; Grever, MR; Johnson, AJ; Kraut, EH; Lin, TS; Mitchell, SM; Moran, ME; Porcu, P; Ruppert, AS; Schaaf, LJ | 1 |
| Andritsos, L; Blum, KA; Byrd, JC; Flynn, JM; Grever, MR; Gupta, SV; Gurcan, M; Herman, SE; Johnson, AJ; Jones, JA; Kong, H; Lehman, A; Lucas, DM; Mahoney, E; Smith, LL; Wagner, AJ; Yeh, YY; Zhang, X | 1 |
| Andritsos, L; Brown, JR; Bühler, A; Byrd, JC; Caligaris-Cappio, F; Devin, J; Gabrilove, J; Ghia, P; Grever, MR; Hallek, M; Heerema, NA; Janssens, A; Johnson, AJ; Kipps, TJ; Lanasa, MC; Larson, RA; Leblond, V; Milligan, DW; Stilgenbauer, S | 1 |
3 trial(s) available for fludarabine and alvocidib
| Article | Year |
|---|---|
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cell Cycle; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Inactivation, Metabolic; Infusions, Intravenous; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Piperidines; Protein Kinase Inhibitors; Recurrence; Salvage Therapy; Treatment Outcome; Tumor Lysis Syndrome; Uridine Diphosphate Glucuronic Acid; Vidarabine | 2009 |
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Rituximab; Vidarabine | 2010 |
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Recurrence; Survival Analysis; Treatment Failure; Vidarabine | 2015 |
5 other study(ies) available for fludarabine and alvocidib
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Cycle Proteins; Chromosomes, Human, Pair 17; Cyclin-Dependent Kinase Inhibitor p27; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Enzyme Precursors; Flavonoids; Gene Deletion; Genes, p53; Growth Inhibitors; Humans; In Situ Hybridization, Fluorescence; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; Microtubule-Associated Proteins; Neoplasm Proteins; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 1998 |
Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Drug Resistance, Neoplasm; Flavonoids; Flow Cytometry; Humans; Lethal Dose 50; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine | 2001 |
MicroRNAs in leukemia.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Disease Progression; Flavonoids; Gene Expression Regulation, Leukemic; Humans; Leukemia; Mice; MicroRNAs; Piperidines; Prognosis; Vidarabine | 2006 |
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
Topics: Antineoplastic Agents; Autophagy; Cell Culture Techniques; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Flavonoids; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Signal Transduction; Starvation; Tumor Cells, Cultured; Vidarabine | 2012 |